Navigation Links
Additional Analysis from Two-Year Sequel Study of QNEXA Featured at The 2011 Annual Scientific Meeting of The Obesity Society
Date:9/29/2011

MOUNTAIN VIEW, Calif., Sept. 29, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that multiple abstracts will be presented at Obesity 2011, the 29th Annual Scientific Meeting of The Obesity Society, to be held October 1st to October 5th, 2011 in Orlando, Florida. The Obesity Society's Annual Scientific Meeting has grown to be one of the largest gatherings of obesity professionals worldwide.

The posters will be displayed in the Cypress Ballroom of the Orlando World Center Marriott on October 3, 2011 from 9:30 a.m. to 1:45 p.m. Eastern Time (ET) and from 3:00 p.m. to 6:30 p.m. ET. Authors will be available at the posters on October 3, 2011 from 12:30 p.m. to 1:30 p.m. ET.Title:  

Weight Loss With Controlled-Release Phentermine/Topiramate is Associated With Significant Reductions in Use of Concomitant Medications for Cardiometabolic Diseases Over 108 WeeksAuthors:  

W. Timothy Garvey, MD; Thomas Najarian, MD; Craig Peterson, MSPoster Number:

594-PTitle:  

Weight Loss With Low-Dose, Controlled-Release Phentermine/Topiramate Correlates With Improvements in Liver Function in Overweight/Obese Adults With Elevated Alanine AminotransferaseAuthors:  

Samuel Klein, MD; Thomas Najarian, MD; Barbara Troupin, MD, MBA; Wesley W. Day, PhD  Poster Number:

596-PTitle:  

Severely Obese Adults Administered Controlled-Release Phentermine/Topiramate Maintained Their Weight Loss in the Second YearAuthors:  

Kishore M. Gadde, MD; David B. Allison, PhD; Peter Y. Tam, MBA; Barbara Troupin, MD, MBAPoster Number:

593-PAbout QNEXA Controlled Release CapsulesQNEXA [kyoo-nek-suh] is an investigational drug candidate being developed to address weight loss, type 2 diabetes and obstructive sleep apnea. QNEXA is a once-a-day, proprietary, oral, controlled-release formulation of low-dose phentermine and topiramate, which is designed to decrease appetite and increase satiety (the sense of feeling full), the two main mechanisms that impact eating behavior. In phase 2 and 3 clinical data to date, patients taking QNEXA have demonstrated statistically significant weight loss, glycemic control, and improvement in cardiovascular risk factors when used in combination with a diet and lifestyle modification program.

About VIVUS VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead investigational product in clinical development, QNEXA®, has completed phase 3 clinical trials for the treatment of obesity and is currently being considered for approval by US and EU regulators. VIVUS received a Complete Response Letter, or CRL, to the initial QNEXA NDA on October 28, 2010. QNEXA is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS has submitted an NDA for avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. For more information about the company, please visit www.vivus.com.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate" and "intend," among others. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, the timing and substance of our response to the FDA's requests from the End of Review meeting; our response to, and continued dialogue with, the FDA relating to matters raised in the FDA's CRL; the timing and results of the retrospective observational study of fetal outcomes in infants born to mothers exposed to topiramate during pregnancy; the FDA's interpretation of and agreement with the information VIVUS submitted and may submit relating to teratogenicity and cardiovascular safety; the FDA's interpretation of the data from our SEQUEL study, or OB-305; the FDA's requests, if any, to conduct additional prospective studies or retrospective observational studies or to provide further analysis of clinical trial data; the review and questions from the EMA and CHMP on the MAA; substantial competition; the impact on future sales based on specific indication and contraindications contained in the label and the extent of the Risk Evaluation and Mitigation Strategies program; uncertainties of litigation and intellectual property and patent protection; reliance on sole-source suppliers; limited sales and marketing resources and dependence upon third parties; risks related to the development of innovative products; risks related to the failure to obtain FDA or foreign authority clearances or approval; noncompliance with FDA or foreign regulations; and our dependence on the performance of our collaborative partners. As with any pharmaceutical in development, there are significant risks with development, regulatory approval, and commercialization of new products. There are no guarantees that our response to the FDA's CRL or the results of the retrospective observational study of fetal outcomes in infants born to mothers exposed to topiramate during pregnancy and subsequent meetings and communications will be sufficient to satisfy the FDA's safety concerns, that the FDA will not require us to conduct any additional  prospective studies or retrospective observational studies, or that any product will receive regulatory approval for any indication or prove to be commercially successful. VIVUS does not undertake an obligation to update or revise any forward-looking statements. Investors should read the risk factors set forth in VIVUS' Form 10-K for the year ending December 31, 2010, and periodic reports filed with the Securities and Exchange Commission.

CONTACT:   VIVUS, Inc.Investor Relations: The Trout GroupTimothy E. Morris

Brian Korb Chief Financial Officer

bkorb@troutgroup.com650-934-5200

646-378-2923
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Unilife CEO to Purchase an Additional U.S. $500,000 in Company Shares by September 30, 2011
2. PLC Receives Two Additional U.S. Patents and First Japanese Patent For Its RenalGuard® Technology
3. Ingenuity Announces New Additional MicroRNA Content to Complement First-of-its-Kind MicroRNA Filtering Capability in IPA
4. Bionovo Announces an Additional 180 Day Period to Regain Compliance With Nasdaqs Bid Price Rule
5. ViroPharma Announces Additional Securities Repurchase Program
6. Omeros Unlocks Four Additional Orphan GPCRs
7. Auxilium Pharmaceuticals Announces Additional Data from Three-Year XIAFLEX® Recurrence Study in Dupuytrens Contracture in E-poster at ASSH Meeting
8. Auxilium Pharmaceuticals, Inc. and BioSpecifics Technologies Corp. Announce Plans to Develop Additional Indications using XIAFLEX®
9. Elsevier / MC Strategies Introduces Additional Resources to its ICD-10 Roadmap, Helping Healthcare Organizations Prepare for October 2013
10. HASCO Medical Chairman Provides $2 Million in Capital and a Personal Guarantee on Additional $2 Million Promissory Note
11. Nephros Receives 510k Approval to Market Additional Ultrafiltration Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... UAE, May 23, 2016 Experts ... of Precision Medicine and the role of technology ...   The First International Conference of VPS-Penn Medicine ... distinguished patronage and presence of Sheikh Nahyan bin Mubarak Al ... in Precision Medicine, which helps provide personalized medicine and tailor-made ...
(Date:5/23/2016)... 23, 2016 The global  reprocessed ... billion by 2022, according to a new study by ... waste coupled with the lack of centralized support for ... drive the demand for reprocessed medical devices market. Additionally, ... to that of the original device is the high ...
(Date:5/22/2016)... DS Biopharma (DS) today ... compound DS102 in chronic obstructive pulmonary disease (COPD) ... patients. Recent DS preclinical data suggests ... and has bronchodilatory, anti-inflammatory and anti-fibrotic properties in ... will publish further detail on these findings later ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... ... Loma Linda University Health (LLUH) has officially broken ground on the hospital ... people looked on as the shovels hit the dirt at the community groundbreaking event ... the program, Richard H. Hart, MD, DrPH, president, LLUH, recapped the history of the ...
(Date:5/24/2016)... ... ... Boyd Industries, a leading supplier of dental chairs and cabinetry , ... pediatric dentistry , at AAPD 2016, the annual conference and trade show of the ... Unit keeps dental hand pieces and other anxiety-provoking pieces of the dental delivery system ...
(Date:5/24/2016)... ... May 24, 2016 , ... A newly released report reveals that ... access to trusted resources, both in face-to-face interactions and online. In “Heard, Not Judged ... concluded that the creative use of mobile digital devices can be an effective tool ...
(Date:5/24/2016)... ... May 24, 2016 , ... Growing in popularity, more and more people continue ... available and easily accessible. Whether someone chooses to cut gluten out of their life ... King Kullen Grocery stocks their shelves with many different gluten-free products all year round. ...
(Date:5/24/2016)... ... 24, 2016 , ... American Gene Technologies International, Inc ... its board of directors. Otterstatter is co-founder, president and CEO of Preventice, ... that lead to broad-based healthcare solutions. , “Jon knows how to create disruptive ...
Breaking Medicine News(10 mins):